Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allopurinol for Prevention of Cardiovascular Events in High-Risk Patients Including Long-COVID
2024-517610-15-00Phase 3Authorised
- Sponsor
- Poznan University of Medical Sciences
- Start
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in hyperuricemia, hypertension (HTN), ischemic stroke and 8 more comparing Allopurinol (Milurit) with Placebo (2 arms). Primary endpoint: Major adverse cardiovascular events (MACE). Planned start Mar 2024; status: authorised.
02
Drugs
allopurinol
03
Conditions
hyperuricemiahypertension (HTN)ischemic strokeintracerebral hemorrhage (ICH)transient ischaemic attack (TIA)
Beyond the preview
Go deeper on 2024-517610-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517610-15-00.